VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 83 filers reported holding VAXCYTE INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,876,410 | +5.9% | 154,500 | +3.7% | 0.01% | +20.0% |
| Q2 2023 | $7,441,060 | +66.4% | 149,000 | +24.9% | 0.01% | +66.7% |
| Q1 2023 | $4,471,364 | -25.8% | 119,300 | -5.1% | 0.00% | -25.0% |
| Q4 2022 | $6,027,315 | +202.6% | 125,700 | +51.4% | 0.00% | +300.0% |
| Q3 2022 | $1,992,000 | +15.0% | 83,000 | +4.3% | 0.00% | 0.0% |
| Q2 2022 | $1,732,000 | +43.4% | 79,600 | +59.2% | 0.00% | 0.0% |
| Q1 2022 | $1,208,000 | +10.6% | 50,000 | +8.9% | 0.00% | 0.0% |
| Q4 2021 | $1,092,000 | -4.1% | 45,900 | +2.2% | 0.00% | 0.0% |
| Q3 2021 | $1,139,000 | +12.7% | 44,900 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $1,011,000 | +48.5% | 44,900 | +30.1% | 0.00% | – |
| Q1 2021 | $681,000 | -25.7% | 34,500 | 0.0% | 0.00% | -100.0% |
| Q4 2020 | $917,000 | – | 34,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |